chufangao/CTO huggingface dataset:
Clinical trial NCT02867618: Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Official title: Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: PI left institution
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-16
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Baseline population: 3 out of 14 subjects were enrolled but not accrued into study; however, baseline information was collected for all 14 subjects.
Plan to share individual participant data: NO
Clinical trial NCT04975022: A Study Evaluating the Bioavailability of Oral Insulin (N11005)
Official title: Research on Clinical Application of New Therapies for Diabetes and Its Complications and Related Translational Medicine Research
Sponsor: Beijing Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-10
Primary completion date: 2020-08-14
Completion date: 2020-08-14
Clinical trial NCT02201108: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Official title: A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Acronym: TERIKIDS
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 166.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-16
Primary completion date: 2019-10-25
Completion date: 2024-07-29
Baseline population: Analysis was performed on all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03099499: Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Official title: A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Sponsor: Fox Chase Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-08
Primary completion date: 2020-09-09
Completion date: 2020-09-09
Plan to share individual participant data: NO
Clinical trial NCT03616470: Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Official title: A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: GlycoMimetics Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Trial failed to meet primary endpoint.
Enrollment: 388.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-15
Primary completion date: 2024-03-31
Completion date: 2024-03-31
Clinical trial NCT02704754: Suvorexant and Trauma Related Insomnia
Official title: Suvorexant and Trauma Related Insomnia
Sponsor: Howard University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-01
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Plan to share individual participant data: YES
IPD sharing description: Reasonable requests will be accomodated via emailing the principal investigator.
IPD time frame: now, for 5 years
IPD access criteria: reasonable request made directly to investigator
Clinical trial NCT01954966: Progesterone and Brain Imaging Study
Official title: Multimodal Imaging of Progesterone/Neurosteroid Effects in Nicotine Addiction
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 81.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-11-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Baseline population: A total of 81 participants were enrolled, but N = 15 were lost to early follow-up and were not randomized. Therefore, the analysis cohort includes N = 66 participants.
Clinical trial NCT02753127: A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Official title: A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).
Acronym: CanStem303C
Sponsor: Sumitomo Pharma America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1253.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2020-04-28
Completion date: 2021-05-12
Clinical trial NCT04474210: A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants
Official title: An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-56136379 in Adult Participants
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic Decision
Enrollment: 1.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-08-19
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT02126579: Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Official title: Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Acronym: MEL60
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 8.0
Start date: 2014-05-01
Primary completion date: 2019-11-20
Completion date: 2021-05-05
Clinical trial NCT03964337: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
Official title: A Phase II, Open-Label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC)
Acronym: SPARC
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Poor accrual.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-17
Primary completion date: 2021-06-04
Completion date: 2021-06-04
Baseline population: Study accrual was discontinued prior to enrolling any participants in the control arm (Immediate Prostatectomy, Arm B).
Limitations and caveats: Study accrual was discontinued prior to enrolling any participants in the control arm (Immediate Prostatectomy, Arm B).
Plan to share individual participant data: NO
Clinical trial NCT03980184: Guanfacine to Improve Substance Use Outcomes in Women
Official title: The Use of Guanfacine (GUA) (3mg/Day) to Reduce Drug Craving, Improve Cognitive Flexibility and Result in Associated Lower Drug Use in Women With Substance Use Disorder (SUD).
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 74.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-01
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Baseline population: Data represented here is from participants that started treatment.
Limitations and caveats: Small sample sizes, sample being limited to men were limitations. Caveats include small sample size limited examining treatment effects for specific drug use. Also, medication compliance moderated guanfacine effects on primary and secondary outcomes.
Clinical trial NCT02811783: Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Official title: A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Sponsor: Elorac, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 59.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-31
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT04498325: Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
Official title: A Phase I and Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Principal investigator is leaving the institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-31
Primary completion date: 2022-04-30
Completion date: 2022-04-30
Plan to share individual participant data: NO
Clinical trial NCT01877655: A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Acronym: HELIOS
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 514.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-09-11
Primary completion date: 2017-09-28
Completion date: 2022-03-01
Baseline population: The analysis population was the All Randomized which consisted of all randomized participants whether they received study drug or not.
Limitations and caveats: In Oct 2014 data monitoring committee informed Astellas of the results of the first futility analysis. The FDA considered data for 68 participants included in futility analysis compromised and asked that it is not included in final efficacy analysis.
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT02407236: A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Acronym: UNIFI
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 961.0 (ACTUAL)
Number of arms: 10.0
Start date: 2015-07-10
Primary completion date: 2018-08-10
Completion date: 2021-11-30
Baseline population: The primary efficacy analysis set consisted of all participants randomized in the study.
Clinical trial NCT04047420: Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally
Official title: A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-11
Primary completion date: 2021-03-03
Completion date: 2021-04-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04001231: Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
Official title: A Phase 1, Open-Label Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety, and Tolerability of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The study is stopped based upon strategic considerations impacting the clinical development of exenatide once-weekly suspension in China
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-30
Primary completion date: 2021-07-02
Completion date: 2021-07-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04236141: A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Official title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor's decision, no safety concerns
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-10
Primary completion date: 2021-07-12
Completion date: 2022-02-07
Baseline population: ITT population included all participants randomized, whether or not the participants received the assigned treatment.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04346667: Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds
Official title: Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
Acronym: PEACE
Sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Poor accrual.
Enrollment: 125.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-14
Primary completion date: 2020-08-23
Completion date: 2020-08-30
Plan to share individual participant data: NO
Clinical trial NCT02998047: A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Official title: A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Sponsor: Actinium Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Poor recruitment
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-31
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Plan to share individual participant data: NO
Clinical trial NCT02466074: Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
Official title: Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
Acronym: perfuseMS
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Inadequate recruitment; termination of funding
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-17
Primary completion date: 2022-02-07
Completion date: 2022-02-07
Baseline population: No participants were assigned to the placebo arm.
Plan to share individual participant data: NO
Clinical trial NCT00490139: ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Official title: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
Acronym: ALTTO
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 8382.0 (ACTUAL)
Number of arms: 4.0
Start date: 2007-05-16
Primary completion date: 2013-12-06
Completion date: 2021-07-01
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04907968: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
Official title: Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)
Acronym: UPGRADE
Sponsor: Mersana Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study Terminated by Sponsor
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-11
Primary completion date: 2023-10-03
Completion date: 2023-10-03
Clinical trial NCT02876328: Partnership for Research on Ebola VACcinations
Official title: Partnership for Research on Ebola VACcinations (PREVAC)
Acronym: PREVAC
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 4789.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-03-27
Primary completion date: 2019-12-24
Completion date: 2023-12-20
Clinical trial NCT02761694: Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
Official title: A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Reasons
Enrollment: 78.0 (ACTUAL)
Number of arms: 12.0
Start date: 2016-06-26
Primary completion date: 2021-03-10
Completion date: 2021-03-10
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT02277613: A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
Official title: A Phase 2 Prospective, Randomized, Double-blind, Sham-controlled, Parallel-group, Multi-center Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
Acronym: MI-NSTEMI
Sponsor: Healios K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-31
Primary completion date: 2019-06-30
Completion date: 2020-01-31
Clinical trial NCT00667823: Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Official title: Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Acronym: SERAPHIN OL
Sponsor: Actelion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 550.0 (ACTUAL)
Number of arms: 1.0
Start date: 2008-10-17
Primary completion date: 2020-12-07
Completion date: 2020-12-07
Limitations and caveats: The limitation of the open-label study design was the open label nature of the trial due to which the number of participants decreased over time to the extent that 10 percent (%) and 2.4% of participants (N=550) remained in the study at Years 7 and 9, respectively.
Clinical trial NCT02333149: Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population
Official title: Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population
Acronym: MYNAP
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Issues surrounding the current COVID-19 pandemic.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-01
Primary completion date: 2021-11-04
Completion date: 2021-11-04
Clinical trial NCT04035564: Early Sodium Intake in Preterm Newborns
Official title: Early Sodium Intake in Preterm Newborns; Randomized Clinical Trial
Sponsor: Hospital del Niño Dr. Federico Gomez Santos (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-30
Primary completion date: 2020-03-02
Completion date: 2020-03-20
Limitations and caveats: Small numbers of subjects analyzed.
Plan to share individual participant data: NO